Da Kang
ABSTRACT
The pandemic of Covid-19 has caused great harm to the world. Curbing the spread of the virus is therefore important to prevent and stop possible future outbreaks. The SARS-CoV-2 genome encodes an important papain-like protease (PLpro), which is located in its non-structural protein 3 (NSP3). PLpro is an essential cysteine protease, capable of cutting viral polyproteins, and has the ability to remove ubiquitin and ubiquitin-like proteins, so it is an important antiviral target. The kinetic and thermodynamic parameters of PLpro are essential to understanding the mechanism of enzymatic activity and inhibition. In this paper, the PLpro of SARS-CoV and SARS-CoV-2 are compared and introduced in detail, and the data of their kinetic parameters and thermodynamic parameters are reviewed. Finally, we explain the mechanism of PLpro function and the inhibitory mechanism of GRL0617.
- Forster P., Forster L., Renfrew C., Phylogenetic network analysis of SARS-CoV-2 genomes. PNAS. 2020; 117: 9241-9243Google Scholar
- Gorla U.S., Rao G.K. SARS-CoV-2: The prominent role of non-structural proteins (NSPS) in COVID-19. Indian J Pharm Educ. 2020; 54(3): S381-389Google Scholar
- Freitas B.T., Durie I.A., Murray J., Characterization and noncovalent inhibition of the deubiquitinase and deISGylase activity of SARS-CoV-2 papain-like protease. ACS Infect Dis. 2020; 6: 2099-2109Google Scholar
- Yan S.M., Wu G. Spatial and temporal roles of SARS-CoV PLpro–A snapshot. The FASEB Journal. 2021; 35: e21197Google Scholar
- Ratia K., Kilianske A., Baez-Santos Y.M., Structural basis for the ubiquitin-linkage specificity and deISGlating activity of SARS-CoV papain-like protease. PLoS Pathog. 2014; 10 (5): e1004113Google Scholar
- Swatek K.N., Aumayr M., Pruneda J.N., Irreversible inactivation of ISG15 by a viral leader protease enables alternative infection detection strategies. PNAS. 2018; 115: 2371-2376Google Scholar
- Klemm T., Ebert G., Calleja D.J., Mechanism and inhibition of the papain-like protease, PLpro, of SARS-CoV-2. EMBO J. 2020; 39: e106275Google Scholar
- Shin D., Mukherjee R., Papain-like protease protease regulates SARS-CoV-2 viral spread and innate immunity. Nature. 2020; Vol 587: 657-662Google Scholar
- Gao X.P., Qin B., Chen P., Crystal structure of SARS-CoV-2 papain-like protease. Acta Pharm Sin B. 2021; 11(1): 237-245Google Scholar
- Ma C.L., Sacco M.D., Xia Z.L., Discovery of SARS-CoV-2 papain-like protease inhibitors through a combination of high-throughput screening and a flipGFP-based reporter assay. ACS Cent. Sci. 2021; 7: 1245-1260Google Scholar
- Rut W., Lv ZY., Zmudzinske M., Activity profiling and crystal structures of inhibitor bound SARS-CoV-2 papain-like protease: A framework for anti-COVID-19 drug design. Sci. Adv. 2020; 6: eabd4596Google Scholar
- Thurakkal L., Singh S., Roy R., An in-silico study on selected organosulfur compounds as potential drugs for SARS-CoV-2 infection via binding multiple drug targets. Chem Phys Lett. 2021; 763: 138193Google Scholar
- Naidoo D., Kar P., Roy A., Structural insight into the binding of cyanovirin-N with the spike glycoprotein, Mpro and PLpro of SARS-CoV-2: Protein-protein interactions, dynamics simulations and free energy calculations. Molecules. 2021; 26: 5114Google Scholar
- Sanachai K., Mahalapbutr P., Lee V.S., In silico elucidation of potent inhibitors and rational drug design against SARS-CoV-2 papain-like protease. J. Phys. Chem. B. 2021; 125: 13644-13656Google Scholar
- Bhowmick S., AlFaris N.A., ALTamimi J.Z., Identification of bio-active food compounds as potential SARS-CoV-2 PLpro inhibitors-modulators via negative image-based screening and computational simulations. Comput Biol Med. 2022; 145: 105474Google Scholar
- Singh E., Jha R.K., Khan R.J., Kumar A., A computational essential dynamics approach to investigate structural influences of ligand binding on papain like protease from SARS-CoV-2. Comput Biol Chem. 2022; 99: 107721Google Scholar
- Qayed W.S., Ferreira R.S., Silva J.R.A. Insilico study towards repositioning of FDA-approved drug candidates for anticoronaviral therapy: molecular docking, molecular dynamics and binding free energy calculations. Molecules. 2022; 27: 5988Google Scholar
- Chou C.Y., Lai H.Y., Chen H.Y., Structural basis for catalysis and ubiquitin recognition by the severe acute respiratory syndrome coronavirus papain-like protease. Acta Cryst. 2014; 70: 572-581Google Scholar
- Chou C.Y., Lai H.Y., Chen H.Y., Structural basis for catalysis and ubiquitin recognition by the Severe acute respiratory syndrome coronavirus papain-like protease. Acta Cryst. 2014; D70: 572-581Google Scholar
- Patchaett S., Lv Z.Y., Rut W., A molecular sensor determines the ubiquitin substrate specificity of SARS-CoV-2 papain-like protease. Cell Rep. 2021; 26: 10754.Google Scholar
- Ratia K., Pegan S., Takayama J., A noncovalent class of papain-like protease/deubiquitinase inhibition blocks SARS virus replication. Proc. Natl. Acad. Sci. 2008; 105 (42): 16119-16124Google Scholar
- Lee H., Lei H., Santarsiero B.D., Inhibitor recognition specificity of MERS-CoV papain-like protease may differ from that of SARS-CoV. ACS Chem. Biol. 2015; 10: 1456-1465.Google Scholar
- Osipiuk J., Azizi S.-A., Dvorkin S., Structure of Papain-like Protease from SARS-CoV-2 and its Complexes with Non-covalent Inhibitors. Nat. Commun. 2021; 12 (1), 743Google Scholar
- Shan H.Y., Liu J.P., Shen J.L., Development of potent and selective inhibitors targeting the papain-like protease of SARS-CoV-2. Cell Chem. Biol 28, 2021; 28: 855-865Google ScholarCross Ref
Index Terms
- The Kinetic parameters, Thermodynamic parameters, and Mechanism of PLpro from SARS-CoV and SARS-CoV-2
Recommendations
SARS-CoV-2 proteases Mpro and PLpro: Design of inhibitors with predicted high potency and low mammalian toxicity using artificial neural networks, ligand-protein docking, molecular dynamics simulations, and ADMET calculations
AbstractThe main (Mpro) and papain-like (PLpro) proteases are highly conserved viral proteins essential for replication of the COVID-19 virus, SARS-COV-2. Therefore, a logical plan for producing new drugs against this pathogen is to discover inhibitors ...
Graphical abstractDisplay Omitted
Highlights- Pyrazolopyridazines found in silico as new class of potential Mpro/PLpro inhibitors.
- Docking and MD indicate stable binding of lead compounds to catalytic active sites.
- Docking and MD show stable binding of 3 compounds to Mpro ...
The interaction of the bioflavonoids with five SARS-CoV-2 proteins targets: An in silico study
AbstractFlavonoids have been shown to have antioxidant, anti-inflammatory, anti-proliferative, antibacterial and antiviral efficacy. Therefore, in this study, we choose 85 flavonoid compounds and screened them to determine their in-silico ...
Highlights- Investigate the in-silico interaction of flavonoid compounds with protein targets crucial for SARS-CoV-2 infection.
Potential inhibitors of the main protease of SARS-CoV-2 and modulators of arachidonic acid pathway: Non-steroidal anti-inflammatory drugs against COVID-19
AbstractThe main protease of SARS-CoV-2 is one of the key targets to develop and design antiviral drugs. There is no general agreement on the use of non-steroidal anti-inflammatory drugs (NSAIDs) in COVID-19. In this study, we investigated ...
Highlights- The use of non-steroidal anti-inflammatory drugs (NSAIDs) in COVID-19 has been discussed.
Comments